Day February 3, 2026

HMN 2026: How Progression-free survival is prolonged with sacituzumab govitecan plus pembrolizumab in triple-negative breast cancer

For patients with previously untreated, programmed death ligand 1 (PD-L1)-positive, locally advanced unresectable or metastatic triple-negative breast cancer (TNBC), sacituzumab govitecan plus pembrolizumab yields significantly longer progression-free survival than chemotherapy plus pembrolizumab, according to a study published in the Jan.…